PHIO PHARMACEUTICALS CORP. Payments for Repurchase of Redeemable Preferred Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- PHIO PHARMACEUTICALS CORP. payments for repurchase of redeemable preferred stock for the quarter ending 2024-12-31 was $0.00.
- PHIO PHARMACEUTICALS CORP. payments for repurchase of redeemable preferred stock for the quarter ending 2024-09-30 was $0.00.
- PHIO PHARMACEUTICALS CORP. payments for repurchase of redeemable preferred stock for the quarter ending 2024-06-30 was $0.00.
- PHIO PHARMACEUTICALS CORP. payments for repurchase of redeemable preferred stock for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- PHIO PHARMACEUTICALS CORP. payments for repurchase of redeemable preferred stock for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- PHIO PHARMACEUTICALS CORP. payments for repurchase of redeemable preferred stock for fiscal 2023 was $2.00K.
- PHIO PHARMACEUTICALS CORP. payments for repurchase of redeemable preferred stock for fiscal 2022 was $0.00.
| Period end | Payments for Repurchase of Redeemable Preferred Stock 3 month | Payments for Repurchase of Redeemable Preferred Stock 12 month |
|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 10-K · filed 2025-03-31 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $0.00 derived: sum of 4 quarters · filed 2025-03-31 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | $0.00 derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $2.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $2.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $2.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $2.00K 10-Q · filed 2024-05-09 | $2.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $0.00 10-K · filed 2024-04-01 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |